Absci is trading -10.52% now at $8.42 after August 11, 2026 earnings showed Q2 revenue of $0.3 million versus approximately $1.01 million expected and a $0.21-per-share loss exceeding the $0.19 forecast.
- Revenue missed estimates by approximately 70.3%; EPS loss exceeded expectations by $0.02
- Results triggered a reported 16.6% after-hours decline
- A $100 million financing, including Eli Lilly’s $40 million investment, extends liquidity into late 2028 but did not offset the operating miss.